AK rate linked to contact lens use

Article

Acanthamoeba keratitis (AK) significantly links to the rate of contact lens use, according to a paper in the British Journal of Ophthalmology.

Acanthamoeba keratitis (AK) significantly links to the rate of contact lens use, according to a paper in the British Journal of Ophthalmology.

Dr Shmuel Graffi et al., Department of Ophthalmology, Baruch Padeh Medical Centre, Israel, distributed a survey questionnaire to laboratory managers in Israel. The team aimed to estimate the incidence of AK in the country for the years 2008-2012. The survey included questions on methods used to diagnose AK and the number of positive and negative culture for Acanthamoeba species performed from the years 2008 to 2012.

It was discovered that six laboratories used non-nutrient agar with Escherichia coli as the culture medium, one laboratory used calcofluor-white staining with fluorescent microscopy and two used PCR for diagnosing AK. Of the patients reviewed, 23 AK cases were identified, giving an estimated incidence of 1/1 668552.

Due to the popularity of contact lenses in AK, the lower than expected incidence rate signaled insufficient awareness of AK in Israel.

The abstract can be read here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.